Abstract:The current study is the first to utilize tandem mass tag (TMT)‐labeled liquid chromatography‐mass spectrometry (LC–MS/MS)‐based proteomics in dysferlinopathy research. The study aimed to explore the proteomic landscape and disease‐related alterations in the muscle tissue proteome of 15 patients with dysferlinopathy with varying degrees of dystrophic pathology, alongside age‐matched controls. Through the analysis of expression data from dysferlinopathy‐affected muscles exhibiting diverse pathological changes, we identified several key proteins linked to the dystrophic pathology observed in patients with dysferlinopathy. These findings provide new insights into the pathogenesis of dysferlinopathy and suggest promising targets for future therapeutic interventions. Aims Previous proteomics studies in dysferlinopathy muscle have been limited in scope, often utilizing 2D‐electrophoresis and yielding only a small number of differential expression calls. To address this gap, this study aimed to employ high‐resolution proteomics to explore the proteomic landscapes of dysferlinopathy and analyze the correlation between muscle pathological changes and alterations in protein expression in muscle biopsies. Methods We conducted a comprehensive approach to investigate the proteomic profile and disease‐associated changes in the muscle tissue proteome from 15 patients with dysferlinopathy, exhibiting varying degrees of dystrophic pathology, alongside age‐matched controls. Our methodology encompasses tandem mass tag (TMT)‐labeled liquid chromatography‐mass spectrometry (LC–MS/MS)‐based proteomics, protein–protein interaction (PPI) network analysis, weighted gene co‐expression network analysis, and differential expression analysis. Subsequently, we examined the correlation between the expression of key proteins and the clinical characteristics of the patients to identify pathogenic targets associated with DYSF mutations in dysferlinopathy. Results A total of 1600 differentially expressed proteins were identified, with 1321 showing high expression levels and 279 expressed at lower levels. Our investigation yields a molecular profile delineating the altered protein networks in dysferlinopathy‐afflicted skeletal muscle, uncovering dysregulation across numerous cellular pathways and molecular processes, including mRNA metabolic processes, regulated exocytosis, immune response, muscle system processes, energy metabolic processes, and calcium transmembrane transport. Moreover, we observe significant associations between the protein expression of ANXA1, ANXA2, ANXA4, ANXA5, LMNA, PYGM, and the extent of histopathologic changes in muscle biopsies from patients with dysferlinopathy, validated through immunoblotting and immunofluorescence assays. Conclusions Through the aggregation of expression data from dysferlinopathy‐impacted muscles exhibiting a range of pathological alterations, we identified multiple key proteins associated with the dystrophic pathology of patients with dysferlinopathy. These findings provide novel insights into the pathogenesis of dysferlinopathy and propose promising targets for future therapeutic endeavors.

Apolipoprotein E knockout, but not cholesteryl ester transfer protein (CETP)-associated high-density lipoprotein cholesterol (HDL-C) lowering, exacerbates muscle wasting in dysferlin-null mice

Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice

Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy

Effects of Partial Knockout of Skeletal Muscle Dynamin-Related Protein 1 on Skeletal Muscle Characteristics in Lean and Obese Mice

Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy

Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice

Genome-wide expression analysis comparing hypertrophic changes in normal and dysferlinopathy mice

Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype

Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition

ApoF Knockdown Increases Cholesteryl Ester Transfer to LDL and Impairs Cholesterol Clearance in Fat-Fed Hamsters.

Diaphragm Displays Early and Progressive Functional Deficits in Dysferlin-Deficient Mice

Abstract 417: Elevation Of Serum Hdl And Apoe Level In A Novel Vps35l Deficient Mouse Model

Defective membrane repair in dysferlin-deficient muscular dystrophy

Dysferlinopathy Fibroblasts Are Defective in Plasma Membrane Repair

Amyotrophy Induced by a High-Fat Diet is Closely Related to Inflammation and Protein Degradation Determined by Quantitative Phosphoproteomic Analysis in Skeletal Muscle of C57BL/6 J Mice

Molecular Pathogenesis of Genetic and Inherited Diseases Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin Protein

Impaired skeletal muscle hypertrophy signaling and amino acid deprivation response in Apoe knockout mice with an unhealthy lipoprotein distribution

Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression

Deficiency of coiled-coil domain containing 80 increases plasma cholesterol by decreasing fecal sterols excretion in hypercholesterolemic mice

Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase.

Increased High Density Lipoprotein (HDL), Defective Hepatic Catabolism of ApoA-I and ApoA-II, and Decreased ApoA-I Mrna Inob/ob Mice